Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis
| Autor: | Qi Du, Xueke Fan, Wei Yuhan, Qin Li, Li Li, Xiaoyue Jiang, Teng Li, Mengqi Li, Yingrui Li, Seyed Kariminia |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Combination therapy Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Clinical investigation medicine Humans Combination immunotherapy Adverse effect business.industry Hazard ratio Hematology Odds ratio Combined Modality Therapy Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis Meta-analysis Immunotherapy business |
| Zdroj: | Critical Reviews in Oncology/Hematology. 138:178-189 |
| ISSN: | 1040-8428 |
| DOI: | 10.1016/j.critrevonc.2019.04.008 |
| Popis: | Combination immunotherapy has become an actively growing field of clinical investigation.We searched for clinical trials of combination immunotherapy and calculated the pooled hazard ratio (HR), odds ratio (OR) of clinical outcomes and safety by subgroups of different combination regimens.Totally 28 clinical trials were analyzed. The study showed that the pooled HRs of overall survival and progression-free survival for combination therapy were 0.77 (95% CI: 0.70-0.84, p 0.001) and 0.72 (95% CI: 0.66-0.79, p 0.001) while the pooled OR of high-grade adverse effects was 1.45 (p = 0.004). Subgroup analysis showed that the HR of overal survival were 0.74 (p = 0.005), 0.79 (p 0.001), 0.70 (p = 0.003) and 0.85 (p = 0.052) for immunotherapy combined with immunotherapy, chemotherapy, targeted therapy and radiotherapy group, respectively.The meta-analysis indicated that combination immunotherapy could bring more clinical benefits with increased high-grade adverse effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect